about
P3781
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Advanced MelanomaPeginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By SurgeryCombination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and RibavirinStudy of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C PatientsIntratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis CRandomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected PatientsStudy of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis CRetreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose RibavirinAn Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected IndividualsA Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell CarcinomaRIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of RibavirinInfergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and RibavirinTreatment of Oral Warts in HIV+ PatientsPegasys® in Patients With Myeloproliferative DiseasesEfficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis CABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell CarcinomaA Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis CInterleukin-2 and Interferon in Treating Patients With Metastatic Kidney CancerMedroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney CancerHigh-Dose Interferon Alfa in Treating Patients With Stage II or StageIII MelanomaTaribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal CancerPhase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis CPegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder SubjectsInterferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKIDacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic ImbalanceA Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)EXtended Therapy in Hepatitis C Genotype 3 Infected PatientsHyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder CancerDiscontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-AlphaPROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2bPROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
P4844
Q61713089-3C3C8628-6563-4994-8C26-62598A5FA67FQ61864788-4DC59538-CFF6-42A0-B103-9369FC5F3596Q61914804-F239CB01-1831-400F-B2C8-3C4E3B051ED4Q61915185-60335399-56EE-4D09-AFE7-DA7240FD5E8EQ61915269-35922AD6-D95F-41C4-B540-EC6E3EA5696CQ61915593-A5547FEB-A828-48CB-99D0-83D665C1A9EDQ61917571-27F23E3A-F35C-4065-9D5A-910774E20836Q61917593-BC1B1BC2-2FDC-430E-9115-8DC02E0EC4EEQ61917768-B2211819-BFB3-4F32-8A18-7062177E9B00Q61917984-E414F4F0-CA24-4A01-9DB0-16C004C0BEB2Q61917989-882397D8-F30F-488E-9581-5D628ADC7DC3Q61918148-1FF0CE09-6C89-4236-87A0-F76B5FFAEB4FQ61918300-A38E3ACF-0E98-4868-BD41-FEEAB665B731Q61918501-75C6C7B0-E4D6-4659-BA22-20914CC2778EQ61918517-AC0CF09F-7E74-46A0-95B0-6AC3D8737301Q61920565-D399654E-8F80-4A71-874F-A3AC8130C2A5Q61920736-EBF717E3-D42E-4C93-9F58-763109668896Q61920908-09FCCB54-F9C3-4DB0-8F47-511FEED3D1C2Q61921656-B90CF1D9-A26A-4706-9A3F-28F3A123CA13Q61921872-F1C4AE75-1AB5-4756-AC9B-A69C0A1FA984Q61921931-2345B328-F73A-43EF-B890-44B17850236EQ61921939-0C9B9FBE-8824-44AD-9318-DDBDFF92BD6EQ61922228-E88DA75F-DC22-44F3-A460-BA287A7F2488Q61922352-66541F1F-F910-4A21-A8AD-668BEAF11913Q61922395-9D2EB48D-17E1-4DDE-B033-E136F143286DQ61924318-74320DF0-20E7-4D3D-8E6B-0A7ABA96F518Q61924468-7A75B039-7BE1-468A-91D6-950150A95D43Q61924582-E00D6FEB-95D0-4274-9A4D-C5BF1D627E11Q61932996-6C66725D-8507-471C-98F0-3E6E1023AE5DQ61933098-C07D69EC-7C8A-4A39-90D8-F5D5285932A0Q61933814-50A55821-5C32-42DA-8C17-9AE0600AF44AQ61934642-9E2A6394-A19D-47A0-9A75-16AE0A289EBCQ61936101-A9A32F16-7C91-49C7-B86A-62026FDBC05EQ61936623-AC2317C7-37A9-4220-A93E-983878AFFBB7Q61936662-8D0EC160-585C-44EB-84C6-AB52ADCB8118Q61936715-E4C97B0A-C02E-4F14-AF08-63EF4B465106Q61938459-52AF1802-6E61-4338-95DD-55AF7626F006Q61938792-B6D8075A-D2A2-4281-A555-D9D45113E46AQ61939209-2899F9CE-9A2C-456A-9871-3949840C113EQ61939210-37DBF127-C953-40AE-B279-5B74E37C5211
P4844
description
chemická sloučenina
@cs
chemische Verbindung
@de
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
composé chimique
@fr
name
Interferon-alpha
@en
interféron alpha
@fr
type
label
Interferon-alpha
@en
interféron alpha
@fr
altLabel
Interferon alfa
@en
Interferon alpha
@en
natural alpha interferon
@en
prefLabel
Interferon-alpha
@en
interféron alpha
@fr
P672
P486
P486
P672
D12.644.276.374.440.890.250
D12.776.467.374.440.890.250
D23.529.374.440.890.250
P7830
Alpha_Peginterferon